TNFRSF12A and pancreas disorder: Our data confirm long-term CDE treatment as an experimental regime that recapitulates the hallmarks of chronic pancreatitis and will initiate further studies evaluating TWEAK/Fn14 signalling as a novel therapeutic target in pancreatic disease.